Interim report 2026
Filed with HKEX · Stock code 512 · · 93 pages · English
Dr. Tang Weikun (Chairman) Mr. Zhou Chao (CEO) Mr. Yang Guang Ms. Lam Chit Yee Jessica INDEPENDENT NON-EXECUTIVE DIRECTORS Ms. So Tosi Wan, Winnie Dr. Xing Li Na Dr. Pei Geng Mr. Hu Yebi COMPANY SECRETARY Mr. Foo Tin Chung, Victor AUTHORISED REPRESENTATIVES Dr. Tang Weikun Mr. Foo Tin Chung, Victor AUDIT COMMITTEE Ms. So Tosi Wan, Winnie (Chairwoman) Dr. Xing Li Na Dr. Pei Geng Mr. Hu Yebi REMUNER
Grand Pharmaceutical Group Limited on 6ix
Earlier from Grand Pharmaceutical
- Notification Letter and Reply Form to Non-registered Shareholders - Notice of publication of Interim Report
- Notification Letter and Reply Form to Registered Shareholders - Notice of publication of Interim Report
- The world's first: Grand Pharma's global innovative product STC3141 successfully reached the clinical endpoint in the Phase II clinical study in China
- Voluntary announcement: the global innovation product of The Group STC3141 was approved to commence phase IIa clinical research in related to COVID-19 in Belgium
- China Grand Pharmaceutical and Healthcare: GP (HK)'s First-In-Class Drug STC3141 for Sepsis has been granted A 'Notice of Approval for Clinical Trial of Drugs' issued by the NMPA
Later from Grand Pharmaceutical
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Proposed change of auditors
Follow Grand Pharmaceutical into a list and get an email when it puts out news.
Follow Grand Pharmaceutical